IDDF2021-ABS-0098 Comparison of curative effect between metformin and mesalazine in the treatment of experimental colitis

Abstract

<h3>Background</h3> To evaluate the different efficacy in the treatment of mice colitis between metformin and mesalazine. <h3>Methods</h3> C57BL/6 male mice aged 6-8 weeks were given ad libitum access to 3% dextran sulphate sodium to induce colitis. The treatment groups were administered with metformin and mesalazine, respectively. The body weight, colon length, disease activity index(DAI), histopathological changes and the expression of pro-inflammatory cytokines in each group were evaluated. <h3>Results</h3> Compared to the DSS group, mice treated with metformin or mesalazine simultaneously experienced significantly less bodyweight loss, less DAI scores (IDDF2021-ABS-0098 Figure 1) and less colon length shortening (IDDF2021-ABS-0098 Figure 2). Histological examination showed better histological scores in mesalazine treatment group and metformin treatment group (IDDF2021-ABS-0098 Figure 3). Moreover, metformin or mesalazine could significantly inhibit the mRNA expression levels of IL-6, TNF-α and IL-1β (IDDF2021-ABS-0098 Figure 4). But there was no significant difference between the two treatment groups. <h3>Conclusions</h3> Metformin can ameliorate DSS-induced experimental colitis in mice, and its curative effect is not inferior to that of mesalazine.